In a nutshell This article looked at the use of olmutinib (Olita) in the treatment of T790M-positive non-small cell lung cancer (NSCLC) that was previously unresponsive to a tyrosine kinase inhibitor (TKI). The authors concluded that olmutinib had clinical activity and manageable side effects in these patients. Some background NSCLC accounts for...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of venetoclax (Venclexta) and low-dose navitoclax (ABT-263) in combination with chemotherapy in patients with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL). This study concluded that this treatment option was well tolerated and...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of the BGD (bendamustine, gemcitabine, and dexamethasone) regimen in patients with previously treated Hodgkin lymphoma (HL). This study concluded that BGD is well-tolerated and highly effective in these patients. Some background Hodgkin lymphoma (HL) is a cancer that...
Read More
In a nutshell This study evaluated the effect of daratumumab (Darzalex)-based treatments on sustained minimal residual disease (MRD) negativity and outcomes in patients with relapsed/refractory (RR) multiple myeloma (MM). The data showed that treatments including daratumumab led to sustained MRD negativity and improved outcomes in these...
Read More
In a nutshell This study investigated the effectiveness and safety of combination regimens of brentuximab vedotin (BV; Adcetris), ipilimumab (Yervoy), and nivolumab (Opdivo) in patients with relapsed/refractory Hodgkin lymphoma (HL). The data showed that the treatment combinations had promising effectiveness and manageable side effects. Some background...
Read More
In a nutshell This trial is aiming to examine the safety and effectiveness of an experimental treatment called BPX-063, a CAR-T cell treatment, in patients with advanced HER-2 positive breast cancer. The main outcomes to be measured are the maximum tolerated dose of BPX-603 and the antitumor activity. This trial is being carried out across the...
Read More
In a nutshell This study aimed to investigate the effectiveness of inotuzumab ozogamicin (InO; Besponsa) in patients with Philadelphia chromosome-positive (Ph+) relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL). This study concluded that this treatment is a good option for these patients. Some background Ph chromosome...
Read More
In a nutshell This study investigated if giving patients with aggressive multiple myeloma (MM) a combination of selinexor (Xpovio), bortezomib (Velcade), and dexamethasone (Ozurdex) could improve their survival. The study suggested that this combination improved patients’ outcomes. Some background Multiple Myeloma (MM) is an...
Read More
In a nutshell This study compared the effectiveness of FOLFIRI (5-fluorouracil, folinic acid, and irinotecan) with either cetuximab (Erbitux) or bevacizumab (Avastin) in the treatment of advanced colorectal cancer (CRC). Researchers suggested that FOLFIRI with cetuximab resulted in improved response and longer survival for these patients. Some...
Read More
In a nutshell This study aimed to investigate if tazemetostat (Tazverik) was a safe and effective treatment in patients with relapsed/refractory follicular lymphoma (FL). This study concluded that tazemetostat provided durable responses and was well tolerated in these patients. Some background Tazemetostat is...
Read More
In a nutshell This study investigated whether giving patients with relapsed/resistant multiple myeloma (MM) venetoclax (Venclexta), in combination with bortezomib (Velcade) and dexamethasone (Ozurdex), will improve patient survival. This study showed that these patients would benefit from this treatment combination. Some background...
Read More
In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced solid...
Read More
